Indaptus Therapeutics can sell up to 87,719,298 common shares at an assumed $1.14 each, targeting aggregate gross proceeds of $100,000,000. The issuer would use net proceeds for working capital, corporate purposes and strategic initiatives, while the illustrated transaction would create $0.64 per-share dilution for new investors.

Key Highlights

  • Indaptus intends to direct net proceeds toward working capital, corporate purposes, acquisitions, investments and research collaborations.
  • The offering illustrates net tangible Book Value of $0.50 per share after the transaction, compared with $0.10 per share before it.
  • Indaptus Therapeutics, Inc. (NASDAQ: INDP) may sell up to 87,719,298 shares of common stock at an assumed price of $1.14 per share through an at-the-market offering.

Indaptus Therapeutics, Inc. (NASDAQ: INDP) may sell up to 87,719,298 shares of common stock at an assumed price of $1.14 per share through an at-the-market offering. The issuer is seeking aggregate gross proceeds of up to $100,000,000. At that assumed price, shares outstanding could rise from 133,242,324 immediately before the offering to as many as 220,961,622 afterward.

Actual sales and the resulting share count would vary with the prices available during the offering.

$100M Common Stock Capacity

The common stock carries a Par Value of $0.01 per share.

The new agreement replaces the original arrangement dated June 1, 2022. Wainwright may sell the shares through the Nasdaq Capital Market, another existing U.S. trading market, a market maker, negotiated transactions or direct sales to the agent as principal.

If Indaptus and Wainwright agree to a distribution method other than market sales at prevailing or related prices, the company will provide the required additional offering information.

$1.14 Assumed Offering Price

That figure excludes 104,396 shares issuable through outstanding Options under the Indaptus 2021 Stock Incentive Plan, 23,894 shares reserved for possible future issuance under that plan, 1,676,425 shares covered by warrants with a $1.75 per-share exercise price, and 112,304 shares issuable through remaining warrants.

A separate illustration based on June 30, 2026, shows net tangible book value of $0.10 per share before the transaction. The assumed sale would add $0.40 per share attributable to new investors and produce pro forma net tangible book value of $0.50 per share.

The same table shows dilution of $0.64 per share to purchasers in the offering, while existing stockholders would have approximately $0.40 per-share dilution in net tangible book value.

Working Capital And Strategy

Indaptus intends to use net proceeds for Working Capital and other general corporate purposes. The company has not identified Acquisition targets.

Existing Awards And Warrants

The June 30, 2026, dilution illustration excludes 88,556 shares issuable upon exercise of outstanding options under the 2021 Plan, which carried a weighted exercise price of $64.38. Exercise of outstanding options or warrants, or settlement of restricted stock units in common stock, could create further dilution for investors purchasing shares in the offering.

Peers Moving on This News